ArticleMolecular vision2024
Retinal and metabolic changes in a high-fat diet (HFD)+STZ model of Type II diabetes.
Article in Molecular vision, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KLF10-IN-1 Attenuates RPE Cell Apoptosis and Experimental Diabetic Retinopathy Via the KLF10/PERK/eIF2α/ATF4/CHOP Pathway.Investigative ophthalmology & visual science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
While the high-dose streptozotocin (STZ; 100 mg/kg) rodent model is the gold standard in modeling Type I diabetes, models for Type II diabetes are needed for this more common form of diabetes. We investigated the retinal, cognitive, and metabolic alterations in a Type II diabetic model induced by high-fat diet (HFD) and low-dose STZ (30 mg/kg). Long Evans rats were assigned to naïve control, HFD, or HFD+STZ groups. Diabetic rats were further stratified into Type I and Type II based on metabolic assessments. Optomotor response (OMR, visual function), electroretinograms (retinal function), and Y-maze (cognitive function) were tested. Serum was analyzed for 12 metabolic markers using a multiplex panel. Type I rats showed severe increases in blood glucose accompanied by impairments in insulin and glucose tolerance, reduced bodyweight, and low insulin levels. In contrast, Type II rats showed moderate changes in blood glucose and insulin and glucose tolerance with weights and insulin levels similar to naïve controls. Type I and II rats showed OMR deficits (p<0.05) and electroretinogram changes (p<0.05). No cognitive deficits were observed. Type I rats displayed reduced serum levels of brain-derived neurotrophic factor (BDNF), C-Peptide, and leptin (p<0.05), and alterations in C-Peptide, PYY, and glucagon levels correlated with retinal function changes (p<0.05). Type II rats exhibited a moderate diabetic state while still developing retinal and visual deficits, which recapitulates phenotypes reported in patients.
Indexed as
Identifiers
39959182PMC11829795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.